Huluwa: Obtained the registration certificate of Changchun sedin injection drug

On January 19, Huluwa Pharmaceuticals announced that it had recently received a "Drug Registration Certificate" on Changchun statin injections approved by the State Drug Administration.
this listing application was accepted by the Hainan Provincial Drug Administration in January 2015.
, the company has invested a total of RMB 356.46 million (unaudited) in research and development.
is intended to be used to improve the brain infarction sequelae, cerebral hemorrhage sequelae, cerebral arteriosclerosis and other induced symptoms.
the Spring Cetin injection was first developed by Hungarian company Gedeon Richter and then licensed to be produced by pharmaceutical companies around the world.
the Hungarian original research listed dosage form is an injection, the State Drug Administration has approved Gedeon Richter Plc. Changchun statin injection registered in China, the market specification is 2 ml:10 mg.
according to the website of the State Drug Administration, as of the date of the announcement, in addition to the original research and the company, henan Runhong Pharmaceutical Co., Ltd. and other 12 enterprises have been approved for listing.